Oritavancin

Therapeutic

Treatment of skin infections

Structural features

SMILES

CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2

Sequence

-

Molar mass

1793.12 g/mol

Constitutional members:

N.A.

Natural amino acids

N.A.

D-Amino acids

N.A.

N-terminus

CH3

C-terminus

COOH

Cyclic

yes

Members/cycle

multicyclic

Bond to form cycle

C-O-C; C-C

Lipidation

yes

Glycosylation

yes - 3 sugars

Route of administration

IV

Terminal half-life

245 hours

Protein binding

0.85

Absorption and Bioavailability

-

References